◎ Sugi Atlas

Atlas / Drug / Memantine

Memantine

drug
On this page

Also known as D-145DRG-0267MemantinaNSC-757843SID26751885SID90341818SID104171191SID50104569SID144203750SID170464999MEMANTINE HYDROCHLORIDE

Summary

Memantine (CHEMBL807) is an approved small-molecule dopaminergic agent (ATC N06DX01) targeting GRIN2C; indicated across 43 conditions including dementia and autism spectrum disorder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: N06DX01
  • Targets: 1 (GRIN2C)
  • Indications: 43 conditions
  • Clinical trials: 201
  • Chemistry: 179.3 Da · C12H21N

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL807
NameMemantine
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID4054
ChEBICHEBI:64312
ATCN06DX01
Molecular formulaC12H21N
Molecular weight179.3
InChIKeyBUGYDGFZZOZRHP-UHFFFAOYSA-N

SMILES: CC12CC3CC(C1)(CC(C3)(C2)N)C

IUPAC name: 3,5-dimethyladamantan-1-amine

ChEBI definition: A primary aliphatic amine that is the 3,5-dimethyl derivative of 1-aminoadamantane. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.

Pharmacological roles (ChEBI): dopaminergic agent, antiparkinson drug, NMDA receptor antagonist, neuroprotective agent, antidepressant.

Also known as: D-145, DRG-0267, Memantina, Memantine, NSC-757843, memantine, SID26751885, SID90341818, SID104171191, SID50104569, SID144203750, SID170464999

Parent form; salt/anhydrous children: CHEMBL1699, CHEMBL1882685

Patent coverage: 9,236 distinct patent families (34,597 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
GRIN2CGluN2CAntagonist6.150.2%Q14957

Broader ChEMBL bioactivity targets: 19 (assay-derived). Sample: Prelamin-A/C, Glutamate NMDA receptor; GRIN1/GRIN2B, Glutamate NMDA receptor; GRIN1/GRIN2A, Glutamate NMDA receptor, Estrogen receptor, Glutamate [NMDA] receptor, Glutamate NMDA receptor; Grin1/Grin2b, Glutamate NMDA receptor; Grin1/Grin2a, Acetylcholinesterase, Kappa-type opioid receptor.

Bioactivity

ChEMBL activities: 36 potent at pChembl ≥ 5 of 48 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
GRIN19.02IC500.95nMCHEMBL_ACT_13348817
ACHE8.31IC504.9nMCHEMBL_ACT_23223834
GRIN2D6.27Ki540nMCHEMBL_ACT_22479106
GRIN2D6.27Ki540nMCHEMBL_ACT_844198
Q009616.16Ki700nMCHEMBL_ACT_237414
ACHE6.11IC50780nMCHEMBL_ACT_26154518
GRIN16.11IC50780nMCHEMBL_ACT_29100840
GRIN16.08IC50840nMCHEMBL_ACT_29100834
GRIN16.04IC50911nMCHEMBL_ACT_1912604
GRIN16Ki1000nMCHEMBL_ACT_18854870
P354396IC501000nMCHEMBL_ACT_24920111
GRIN15.99IC501020nMCHEMBL_ACT_1912595
P354395.96IC501090nMCHEMBL_ACT_15718262
GRIN2D5.92Ki1200nMCHEMBL_ACT_14530270
P354395.82IC501500nMCHEMBL_ACT_18854953
P354395.82IC501500nMCHEMBL_ACT_2409408
P354395.82IC501500nMCHEMBL_ACT_2479407
P354395.82IC501500nMCHEMBL_ACT_2586133
P354395.82IC501500nMCHEMBL_ACT_3130499
ESR15.8AC501600nMCHEMBL_ACT_25166919
P354395.58IC502660nMCHEMBL_ACT_26188889
P354395.57EC502720nMCHEMBL_ACT_27394940
GRIN15.5IC503162nMCHEMBL_ACT_29198045
P354395.41AC503937nMCHEMBL_ACT_25120184
GRIN15.36IC504360nMCHEMBL_ACT_14578586
GRIN15.36IC504400nMCHEMBL_ACT_15676411
GRIN15.28IC505200nMCHEMBL_ACT_15676446
GRIN15.26IC505500nMCHEMBL_ACT_3274060
P354395.25IC505570nMCHEMBL_ACT_26188894
GRIN15.25IC505600nMCHEMBL_ACT_3274063

Target pathways

Aggregated over 1 target gene(s): GRIN2C.

Top Reactome pathways

6 total, by targets touching each:

PathwayTargetsGenes
Unblocking of NMDA receptors, glutamate binding and activation1GRIN2C
Neurexins and neuroligins1GRIN2C
Synaptic adhesion-like molecules1GRIN2C
Assembly and cell surface presentation of NMDA receptors1GRIN2C
Negative regulation of NMDA receptor-mediated neuronal transmission1GRIN2C
Long-term potentiation1GRIN2C

Dominant GO biological processes

GO termTargets
glutamate receptor signaling pathway1
brain development1
response to wounding1
directional locomotion1
ionotropic glutamate receptor signaling pathway1
synaptic transmission, glutamatergic1
negative regulation of protein catabolic process1
regulation of synaptic plasticity1
regulation of neuronal synaptic plasticity1
neuromuscular process controlling balance1
positive regulation of synaptic transmission, glutamatergic1
excitatory postsynaptic potential1
long-term synaptic potentiation1
calcium ion transmembrane import into cytosol1
monoatomic cation transmembrane transport1

Indications & clinical

Indications

43 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
dementia4MONDO:0001627HP:0000726
autism spectrum disorder3MONDO:0005258EFO:0003756
fibromyalgia3MONDO:0005546EFO:0005687
obsessive-compulsive disorder3MONDO:0008114EFO:0004242
anxiety3MONDO:0011918EFO:0005230
open-angle glaucoma3MONDO:0005338EFO:0004190
substance-related disorder3MONDO:0002494MONDO:0002491
drug dependence3MONDO:0005303EFO:0003890
depressive disorder3MONDO:0002050MONDO:0002050
Alzheimer disease3MONDO:0004975MONDO:0004975
Parkinson disease3MONDO:0005180MONDO:0005180
migraine disorder3MONDO:0005277MONDO:0005277
multiple sclerosis3MONDO:0005301MONDO:0005301
bipolar disorder3MONDO:0004985MONDO:0004985
autism2MONDO:0005260EFO:0003758
cocaine dependence2MONDO:0005186EFO:0002610
opiate dependence2MONDO:0005530EFO:0005611
neuralgia2MONDO:0021667EFO:0005762
glioblastoma2MONDO:0018177EFO:0000519
heroin dependence2MONDO:0005367EFO:0004240
schizoaffective disorder2MONDO:0005487EFO:0005411
alcohol abuse2MONDO:0002046MONDO:0002046
psychotic disorder2MONDO:0005485EFO:0005407
trichotillomania2MONDO:0013189HP:0012167
amyotrophic lateral sclerosis2MONDO:0004976MONDO:0004976
Huntington disease2MONDO:0007739MONDO:0007739
fragile X syndrome2MONDO:0010383MONDO:0010383
systemic lupus erythematosus2MONDO:0007915MONDO:0007915
nicotine dependence1MONDO:0008575EFO:0003768
obesity disorder1MONDO:0011122EFO:0001073
major depressive disorder1MONDO:0002009MONDO:0002009
central nervous system disorder1MONDO:0002602EFO:0009386
neoplasm1MONDO:0005070MONDO:0004992
central nervous system cancer0MONDO:0002714EFO:0000326
central nervous system neoplasm0MONDO:0006130EFO:1000158

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 201.

Phase distribution

PhaseTrials
PHASE452
PHASE248
PHASE337
Not specified23
PHASE117
PHASE2/PHASE314
PHASE1/PHASE25
EARLY_PHASE15

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00120874PHASE4COMPLETEDMemantine and Comprehensive, Individualized Management of Alzheimer’s Disease and Caregiver Training
NCT00183729PHASE4COMPLETEDMemantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults
NCT00187525PHASE4COMPLETEDA 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
NCT00196703PHASE4UNKNOWNMemantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial
NCT00234637PHASE4COMPLETEDRivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer’s Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
NCT00280774PHASE4COMPLETEDMemantine for Corticosteroid-Induced Mood and Declarative Memory Changes
NCT00283309PHASE4TERMINATEDMemantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes
NCT00305578PHASE4COMPLETEDMemantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression
NCT00305903PHASE4COMPLETEDSafety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer’s Disease
NCT00330655PHASE4COMPLETEDAn Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
NCT00344682PHASE4COMPLETEDMemantine Augmentation of Antidepressants
NCT00371059PHASE4COMPLETEDMemantine for Agitation in Dementia
NCT00401167PHASE4COMPLETEDMemantine for Agitation and Aggression in Severe Alzheimer’s Disease
NCT00439699PHASE4COMPLETEDA Pilot Clinical Trial Of Memantine for Essential Tremor
NCT00462228PHASE4TERMINATEDEffect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury
NCT00469456PHASE4COMPLETEDEffect of Memantine on Functional Communication in Patients With Alzheimer’s Disease
NCT00476008PHASE4COMPLETEDDelaying the Progression of Driving Impairment in Individuals With Mild Alzheimer’s Disease
NCT00505167PHASE4COMPLETEDMemantine Versus Donepezil in Early Stages of Alzheimer’s Disease
NCT00545974PHASE4COMPLETEDMemantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
NCT00551161PHASE4COMPLETEDMagnetic Resonance Spectroscopy Study of Memantine in Alzheimer’s Disease
NCT00586066PHASE4COMPLETEDMemantine and Cognitive Dysfunction in Bipolar Disorder
NCT00586573PHASE4COMPLETEDOpen-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS
NCT00638027PHASE4COMPLETEDMemantine for Spasticity in MS Patients
NCT00640198PHASE4COMPLETEDMemantine and Intensive Speech-Language Therapy in Aphasia
NCT00646204PHASE4COMPLETEDNamenda (Memantine) for Non-motor Symptoms in Parkinson’s Disease
NCT00649220PHASE4TERMINATEDMemantine and Antipsychotics Use
NCT00652457PHASE4COMPLETEDStudy of Memantine to Treat Huntington’s Disease
NCT00757978PHASE4COMPLETEDMemantine as Adjunctive Therapy for Schizophrenia Negative Symptoms
NCT00768261PHASE4COMPLETEDCorticolimbic Degeneration and Treatment of Dementia
NCT00800709PHASE4COMPLETEDMemantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer’s Disease
NCT00855686PHASE4COMPLETEDMemantine Versus Placebo in Parkinson’s Disease Dementia or Dementia With Lewy Bodies
NCT00862940PHASE4COMPLETEDA Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer’s Disease
NCT00866060PHASE4UNKNOWNDonepezil and Memantine in Moderate to Severe Alzheimer’s Disease
NCT00933608PHASE4COMPLETEDEffects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer’s Disease
NCT01025466PHASE4COMPLETEDExelon Patch and Combination With Memantine Comparative Trial
NCT01032759PHASE4TERMINATEDMemantine and Postoperative Pain
NCT01041313PHASE4UNKNOWNMemantine for Post-Operative Pain Control
NCT01108029PHASE4COMPLETEDStudy of Memantine for Gait Disorders And Attention Deficit In Parkinson’s Disease
NCT01112683PHASE4COMPLETEDEfficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
NCT01333865PHASE4COMPLETEDA Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

29 molecules share ≥1 primary target. Top 29 by shared-target count:

MoleculeSourceStatusShared targets
AMANTADINEChEMBL + PubChemPhase 4 (approved)GRIN2C
CHLORPROMAZINEChEMBL + PubChemPhase 4 (approved)GRIN2C
DEXTROMETHORPHANChEMBL + PubChemPhase 4 (approved)GRIN2C
KETAMINEChEMBL + PubChemPhase 4 (approved)GRIN2C
LEVORPHANOLChEMBL + PubChemPhase 4 (approved)GRIN2C
ORPHENADRINEChEMBL + PubChemPhase 4 (approved)GRIN2C
CYCLOSERINEChEMBLPhase 4 (approved)GRIN2C
PROCYCLIDINEChEMBLPhase 4 (approved)GRIN2C
GLUTAMIC ACIDChEMBL + PubChemPhase 3 (approved)GRIN2C
DALZANEMDORChEMBLPhase 3GRIN2C
ESMETHADONEChEMBLPhase 3GRIN2C
ALPHAMETHADOLChEMBLPhase 2GRIN2C
BETAMETHADOLChEMBLPhase 2GRIN2C
BUDIPINEChEMBLPhase 2GRIN2C
DEXTRORPHANChEMBLPhase 2GRIN2C
DIZOCILPINEChEMBLPhase 2GRIN2C
IFENPRODILChEMBLPhase 2GRIN2C
LANICEMINEChEMBLPhase 2GRIN2C
LEVOMETHADONEChEMBLPhase 2GRIN2C
LICOSTINELChEMBLPhase 2GRIN2C
PERZINFOTELChEMBLPhase 2GRIN2C
PHENCYCLIDINEChEMBLPhase 2GRIN2C
RACEMETHORPHANChEMBLPhase 2GRIN2C
RADIPRODILChEMBLPhase 2GRIN2C
SELFOTELChEMBLPhase 2GRIN2C
TEZAMPANELChEMBLPhase 2GRIN2C
TRAXOPRODILChEMBLPhase 2GRIN2C
ZELQUISTINELChEMBLPhase 2GRIN2C
NimodipinePubChemApprovedGRIN2C

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot